FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> FDA | Merck

Merck expands Januvia label

Tools

In a sort of good news/bad news move, the FDA is allowing Merck to expand marketing of the diabetes drug Januvia--but it's also expanding the warnings on Januvia's label.

Now, Merck can sell the drug for use in combo with other diabetes meds, rather than as a supplement to diet and exercise alone. The new label will highlight warnings of hypersensitivity reactions, including the rare-but-deadly Stevens-Johnson syndrome.

- take a look at Merck's release
- read the report from the Houston Chronicle

Related Articles:
ADA meeting sees new data on diabetes drugs. Report
FDA expected to approve Januvia soon. Report

Read more on: Merck | Januvia

Bookmark and Share
Get Your FREE FiercePharma Email Newsletter:
Be the first to comment
More stories about FDA   Merck  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.